Publications by authors named "Izumi Nishikawa"
Article Synopsis
- A study was conducted to assess the safety and effectiveness of sofosbuvir plus ribavirin in elderly patients (≥ 75 years old) with genotype 2 hepatitis C, who were previously excluded from clinical trials.
- The study involved 265 patients and found that the overall sustained virological response rate was 97%, with similar rates among different age groups, including the elderly (98% for those ≥ 75 years old).
- While some elderly patients experienced anemia requiring dosage adjustments, the treatment was deemed highly effective and tolerable for older patients.
Background And Aim: In September 2015, sofosbuvir and ledipasvir were approved for clinical use in Japan for patients infected with genotype 1 hepatitis C virus. We conducted a postmarketing prospective cohort study to elucidate the safety and efficacy of this therapy in a real-world setting.
Methods: We treated 509 patients using standard doses of sofosbuvir and ledipasvir for 12 weeks.
Background And Aim: Nodular gastritis is caused by infection and is associated with the development of diffuse-type gastric cancer. This study examined the clinical characteristics of patients with nodular gastritis, including cancer incidence before and after H. pylori eradication.
View Article and Find Full Text PDF